骨保护素、骨桥蛋白和骨钙素与2型糖尿病心血管事件相关:EXSCEL研究的启示
基于EXSCEL随机临床试验中5,473例2型糖尿病患者的基线及随机化后12个月的血浆样本,采用SomaScan蛋白组学检测四种骨代谢标志物。中位随访期间813例(14.9%)发生主要心血管不良事件(MACE)。骨保护素(HR 1.11;95%CI 1.03-1.20;P=0.0047)和骨桥蛋白(HR 1.10;95%CI 1.02-1.18;P=0.0095)每升高1个标准差与MACE风险增加相关,而骨钙素和硬骨素与MACE无关联。将骨保护素和骨桥蛋白加入传统心血管风险因素模型仅提供微小增量价值(C指数0.629 vs 0.638;似然比检验P<0.001)。
要点
- 在2型糖尿病患者中,骨保护素和骨桥蛋白水平每升高1个标准差分别与MACE风险增加11%和10%相关。
- 骨钙素和硬骨素与MACE无显著关联;骨钙素与全因死亡及心血管死亡呈非线性关联。
- 将骨保护素和骨桥蛋白加入传统风险模型对MACE预测的增量价值很小(C指数0.629 vs 0.638)。
核心结论
- 较高的骨保护素和骨桥蛋白水平与2型糖尿病患者心血管事件风险增加相关,支持骨代谢通路参与心血管疾病的假说。
研究设计与样本
- EXSCEL是一项评估每周一次艾塞那肽对2型糖尿病患者心血管安全性和有效性的随机临床试验。
- 从5,473例试验参与者的基线及随机化后12个月样本中,通过SomaScan蛋白组学检测选取候选生物标志物数据。
- 主要复合结局为心血管死亡、非致死性心肌梗死或非致死性卒中的首次发生(MACE)。
- 采用控制混杂因素的Cox比例风险模型进行时间-事件分析,计算生物标志物浓度每升高1个标准差的危险比(HR)及95%CI。
主要发现
- 主要结局在813例参与者中发生(14.9%)。
- 较高的骨保护素水平与MACE风险增加相关(HR 1.11;95%CI 1.03-1.20;P=0.0047)。
- 较高的骨桥蛋白水平与MACE风险增加相关(HR 1.10;95%CI 1.02-1.18;P=0.0095)。
- 将骨保护素和骨桥蛋白加入包含传统心血管风险因素的临床预测模型,对MACE预测仅提供微小增量价值(C指数0.629 vs. 0.638;似然比检验P<0.001)。
- 骨钙素和硬骨素与MACE无关联;骨钙素与全因死亡及心血管死亡呈非线性关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association of four bone metabolism biomarkers (osteoprotegerin, osteopontin, sclerostin, and osteocalcin) with cardiovascular events in people with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) was a randomized clinical trial evaluating the cardiovascular (CV) safety and efficacy of once-weekly exenatide for patients with T2D. Candidate biomarker data were selected from proteomic profiling performed at baseline and 12 months after randomization samples by SomaScan assay in 5,473 trial participants. The primary composite outcome was the first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke (major cardiovascular events [MACE]). Cox proportional hazards models controlling for confounders were used for time-to-event analyses to calculate hazard ratios (HRs) with 95% CI for a 1 SD increase in the biomarker concentrations. RESULTS: The primary outcome occurred in 813 participants (14.9%). Higher levels of osteoprotegerin (HR 1.11; 95% CI 1.03-1.20; P = 0.0047) and osteopontin (HR 1.10; 95% CI 1.02-1.18; P = 0.0095) were associated with an increased risk of MACE. The addition of osteoprotegerin and osteopontin to a clinical predictive model containing traditional CV risk factors provided minimal incremental value for MACE prediction (C-index 0.629 vs. 0.638; likelihood ratio test P < 0.001). Osteocalcin and sclerostin were not associated with MACE. Osteocalcin had a nonlinear association with all-cause death and with CV death. CONCLUSIONS: Higher levels of osteoprotegerin and osteopontin are associated with an increased risk of CV events in people with T2D, supporting the hypothesis that pathways involved in bone metabolism play a role in CV disease.
引用
- Maddaloni E, Nguyen M, Shah SH, et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care. 2025. PMID: 39576722. doi:10.2337/dc24-1455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。